Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
-
Substrates: -
Products: i.e. 15-hydroxyprostaglandin or (15S)-PGE2
r
(5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
(5Z,8E,10E,12S)-12-hydroxy-5,8,10-heptadecatrienoic acid + NAD+
(5Z,8E,10E)-12-oxo-5,8,10-heptadecatrienoic acid + NADH
11alpha,15(S)-dihydroxy-9-ketoprost-5,13-dienoic acid + NAD(P)+
11alpha-hydroxy-9,15-diketoprost-5,13-dienoic acid + NADH
15(S)-hydroperoxy-5,8,11,13-(Z,Z,Z,E)-eicosatetraenoic acid + NAD+
15-oxo-5,8,11,13-(Z,Z,Z,E)-eicosatetraenoic acid + NADH
-
Substrates: -
Products: -
?
15-hydroxyeicosatetraenoic acid + NAD+
15-ketoeicosatetraenoic acid + NADH
-
Substrates: -
Products: -
?
15-hydroxyprostaglandin + NAD+
15-oxoprostaglandin + NADH + H+
19-hydroxyprostaglandin E1 + NAD+
19-hydroxy-15-oxoprostaglandin E1 + NADH
-
Substrates: -
Products: -
?
20-hydroxyprostaglandin E1 + NAD+
20-hydroxy-15-ketoprostaglandin E1 + NADH
-
Substrates: -
Products: -
?
5,6-chrysenequinone + NADH
?
-
Substrates: -
Products: -
?
5,6-chrysenequinone + NADH
? + H2O2
-
Substrates: formation of potentially hazardous semiquinones, reaction mechanism, overview
Products: -
?
6-keto-prostaglandin E1 + NAD+
? + NADH
-
Substrates: -
Products: -
?
6-keto-prostaglandin F1alpha + NAD+
? + NADH
-
Substrates: -
Products: -
?
6-ketoprostaglandin E1 + NAD+
6,15-diketoprostaglandin E1
-
Substrates: -
Products: -
?
6-ketoprostaglandin F1alpha + NAD+
6,15-diketoprostaglandin F1alpha + NADH + H+
9,10-phenanthrenequinone + NADH
?
-
Substrates: -
Products: -
?
9,10-phenanthrenequinone + NADH
? + H2O2
-
Substrates: formation of potentially hazardous semiquinones, reaction mechanism, overview
Products: -
?
prostaglandin A1 + NAD+
15-ketoprostaglandin A1 + NADH + H+
prostaglandin A1 + NAD+
? + NADH
-
Substrates: -
Products: -
?
prostaglandin A2 + NAD+
15-ketoprostaglandin A2 + NADH + H+
-
Substrates: -
Products: -
?
prostaglandin D1 + NAD+
15-ketoprostaglandin D1 + NADH + H+
-
Substrates: very low activity
Products: -
?
prostaglandin D2 + NAD+
15-ketoprostaglandin D2 + NADH + H+
-
Substrates: -
Products: -
?
prostaglandin D2 + NAD+
? + NADH
-
Substrates: -
Products: -
?
prostaglandin E1 + NAD+
15-ketoprostaglandin E1 + NADH + H+
-
Substrates: -
Products: -
?
prostaglandin E1 + NAD+
15-oxoprostaglandin E1 + NADH + H+
-
Substrates: -
Products: -
r
prostaglandin E1 + NAD+
? + NADH
-
Substrates: -
Products: -
?
prostaglandin E2 + NAD+
15-ketoprostaglandin E2 + NADH + H+
prostaglandin E2 + NAD+
15-oxoprostaglandin E2 + NADH + H+
prostaglandin E3 + NAD+
15-keto-prostaglandin E3 + NADH + H+
-
Substrates: -
Products: -
?
prostaglandin F2alpha + NAD+
15-ketoprostaglandin F2alpha + NADH + H+
prostaglandin F2alpha + NAD+
15-oxoprostaglandin F2alpha + NADH + H+
Substrates: -
Products: -
?
prostaglandin F2alpha + NAD+
? + NADH
-
Substrates: -
Products: -
?
prostaglandin I2 + NAD+
15-ketoprostaglandin I2 + NADH + H+
-
Substrates: -
Products: -
?
additional information
?
-
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
Substrates: -
Products: -
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
Substrates: -
Products: -
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
Substrates: i.e. 15-hydroxyprostaglandin or (15S)-PGE2
Products: -
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
Substrates: i.e. 15-hydroxyprostaglandin or (15S)-PGE2
Products: -
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
Substrates: first step in prostaglandin catabolism
Products: -
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
Substrates: i.e. 15-hydroxyprostaglandin or (15S)-PGE2
Products: -
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
Substrates: first step in prostaglandin catabolism
Products: -
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
Substrates: i.e. 15-hydroxyprostaglandin or (15S)-PGE2
Products: -
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
285919, 285927, 285931, 285938, 654158, 654348, 654361, 654374, 654380, 657209, 667924, 668172, 711448 Substrates: -
Products: -
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
Substrates: -
Products: -
r
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
Substrates: -
Products: -
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
Substrates: i.e. prostaglandin E1
Products: -
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
Substrates: i.e. prostaglandin E1
Products: i.e. 15-ketoprostaglandin E1
r
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
Substrates: catabolism of (15S)-PGE2
Products: -
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
Substrates: first step in prostaglandin catabolism
Products: -
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
Substrates: first step in prostaglnadin catabolism
Products: -
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
Substrates: i.e. 15-hydroxyprostaglandin or (15S)-PGE2
Products: -
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
Substrates: key step in prostaglandin catabolism, enzyme activation leads to reduced cell proliferation, the enzyme is an antagonist of ibuprofen
Products: -
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
Substrates: key step in prostaglandin inactivation
Products: -
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
Substrates: PGE2 degradation
Products: -
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
Substrates: prostaglandin E2, PGE2, a proinflammatory bioactive lipid, promotes cancer progression by modulating proliferation, apoptosis, and angiogenesis, PGE2 is a downstream product cyclooxygenase and is biochemically inactivated by the enzyme
Products: -
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
Substrates: reciprocal regulation of cyclooxygenase-2 and 15-hydroxyprostaglandin dehydrogenase expression in A549 human lung adenocarcinoma cells, overview
Products: -
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
Substrates: the enzyme is a putative cyclooxygenase-2 antagonist and and tumor suppressor
Products: -
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
Substrates: transcriptional regulation and biological functions, the enzyme cooperates with cyclooxygenase-2 to control cellular prostaglandin levels, reciprocal regulation of the two enzymes, overview
Products: -
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
Substrates: i.e. 15-hydroxyprostaglandin or (15S)-PGE2, inactivation
Products: -
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
Substrates: i.e. 15-hydroxyprostaglandin or (15S)-PGE2, substrate binding structure analysis, determination of interactions
Products: -
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
Substrates: i.e. 15-hydroxyprostaglandin or PGE2
Products: -
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
Substrates: -
Products: -
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
Substrates: i.e. 15-hydroxyprostaglandin or (15S)-PGE2
Products: -
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
Substrates: PGE2 degradation
Products: -
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
Substrates: i.e. 15-hydroxyprostaglandin or PGE2
Products: -
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
Substrates: i.e. 15-hydroxyprostaglandin or (15S)-PGE2
Products: -
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
Substrates: -
Products: -
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
Substrates: first step in prostaglandin catabolism
Products: -
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
Substrates: i.e. 15-hydroxyprostaglandin or (15S)-PGE2, best substrate
Products: -
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
Substrates: first step in prostaglandin catabolism
Products: -
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
Substrates: i.e. 15-hydroxyprostaglandin or (15S)-PGE2
Products: -
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
Substrates: -
Products: -
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
Substrates: first step in prostaglandin catabolism
Products: -
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
Substrates: i.e. 15-hydroxyprostaglandin or (15S)-PGE2
Products: -
?
(5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
Substrates: -
Products: -
?
(5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
Substrates: -
Products: -
?
(5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
Substrates: -
Products: -
?
(5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
Substrates: the enzyme catalyzes the oxidation of the 15(S)-hydroxyl group of prostaglandin E2 (PGE2), converting the proinflammatory PGE2 to the anti-inflammatory 15-keto-PGE2 (an endogenous ligand for peroxisome proliferator-activated receptor-gamma [PPAR-gamma])
Products: -
?
(5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
Substrates: -
Products: -
?
(5Z,8E,10E,12S)-12-hydroxy-5,8,10-heptadecatrienoic acid + NAD+
(5Z,8E,10E)-12-oxo-5,8,10-heptadecatrienoic acid + NADH
-
Substrates: -
Products: -
?
(5Z,8E,10E,12S)-12-hydroxy-5,8,10-heptadecatrienoic acid + NAD+
(5Z,8E,10E)-12-oxo-5,8,10-heptadecatrienoic acid + NADH
-
Substrates: -
Products: -
?
11alpha,15(S)-dihydroxy-9-ketoprost-5,13-dienoic acid + NAD(P)+
11alpha-hydroxy-9,15-diketoprost-5,13-dienoic acid + NADH
-
Substrates: -
Products: -
?
11alpha,15(S)-dihydroxy-9-ketoprost-5,13-dienoic acid + NAD(P)+
11alpha-hydroxy-9,15-diketoprost-5,13-dienoic acid + NADH
-
Substrates: -
Products: -
?
11alpha,15(S)-dihydroxy-9-ketoprost-5,13-dienoic acid + NAD(P)+
11alpha-hydroxy-9,15-diketoprost-5,13-dienoic acid + NADH
-
Substrates: NAD+ is much more effective than NADP+
Products: -
?
11alpha,15(S)-dihydroxy-9-ketoprost-5,13-dienoic acid + NAD(P)+
11alpha-hydroxy-9,15-diketoprost-5,13-dienoic acid + NADH
-
Substrates: -
Products: -
?
11alpha,15(S)-dihydroxy-9-ketoprost-5,13-dienoic acid + NAD(P)+
11alpha-hydroxy-9,15-diketoprost-5,13-dienoic acid + NADH
-
Substrates: specific for NAD+
Products: -
?
11alpha,15(S)-dihydroxy-9-ketoprost-5,13-dienoic acid + NAD(P)+
11alpha-hydroxy-9,15-diketoprost-5,13-dienoic acid + NADH
-
Substrates: -
Products: -
?
11alpha,15(S)-dihydroxy-9-ketoprost-5,13-dienoic acid + NAD(P)+
11alpha-hydroxy-9,15-diketoprost-5,13-dienoic acid + NADH
-
Substrates: specific for NAD+
Products: -
?
11alpha,15(S)-dihydroxy-9-ketoprost-5,13-dienoic acid + NAD(P)+
11alpha-hydroxy-9,15-diketoprost-5,13-dienoic acid + NADH
-
Substrates: NADP+ is more effective than NAD+
Products: -
?
11alpha,15(S)-dihydroxy-9-ketoprost-5,13-dienoic acid + NAD(P)+
11alpha-hydroxy-9,15-diketoprost-5,13-dienoic acid + NADH
-
Substrates: -
Products: -
?
15-hydroxyprostaglandin + NAD+
15-oxoprostaglandin + NADH + H+
-
Substrates: -
Products: -
?
15-hydroxyprostaglandin + NAD+
15-oxoprostaglandin + NADH + H+
-
Substrates: physiological inactivation of prostaglandin by catalyzing the first step in catabolism
Products: -
?
6-ketoprostaglandin F1alpha + NAD+
6,15-diketoprostaglandin F1alpha + NADH + H+
-
Substrates: -
Products: -
?
6-ketoprostaglandin F1alpha + NAD+
6,15-diketoprostaglandin F1alpha + NADH + H+
-
Substrates: -
Products: -
?
prostaglandin A1 + NAD+
15-ketoprostaglandin A1 + NADH + H+
-
Substrates: -
Products: -
?
prostaglandin A1 + NAD+
15-ketoprostaglandin A1 + NADH + H+
-
Substrates: -
Products: -
?
prostaglandin E2 + NAD+
15-ketoprostaglandin E2 + NADH + H+
-
Substrates: -
Products: -
?
prostaglandin E2 + NAD+
15-ketoprostaglandin E2 + NADH + H+
-
Substrates: the wild type enzyme is highly active against prostaglandin E2 and NAD+
Products: -
?
prostaglandin E2 + NAD+
15-ketoprostaglandin E2 + NADH + H+
Substrates: -
Products: -
?
prostaglandin E2 + NAD+
15-oxoprostaglandin E2 + NADH + H+
Substrates: -
Products: -
?
prostaglandin E2 + NAD+
15-oxoprostaglandin E2 + NADH + H+
-
Substrates: -
Products: -
r
prostaglandin E2 + NAD+
15-oxoprostaglandin E2 + NADH + H+
-
Substrates: -
Products: -
?
prostaglandin E2 + NAD+
15-oxoprostaglandin E2 + NADH + H+
Substrates: -
Products: -
?
prostaglandin E2 + NAD+
15-oxoprostaglandin E2 + NADH + H+
-
Substrates: -
Products: -
?
prostaglandin E2 + NAD+
15-oxoprostaglandin E2 + NADH + H+
Substrates: -
Products: -
?
prostaglandin E2 + NAD+
15-oxoprostaglandin E2 + NADH + H+
-
Substrates: -
Products: -
?
prostaglandin E2 + NAD+
15-oxoprostaglandin E2 + NADH + H+
Substrates: -
Products: -
?
prostaglandin E2 + NAD+
15-oxoprostaglandin E2 + NADH + H+
-
Substrates: -
Products: -
?
prostaglandin F2alpha + NAD+
15-ketoprostaglandin F2alpha + NADH + H+
-
Substrates: -
Products: -
?
prostaglandin F2alpha + NAD+
15-ketoprostaglandin F2alpha + NADH + H+
-
Substrates: NAD+ is much more effective than NADP+
Products: -
?
prostaglandin F2alpha + NAD+
15-ketoprostaglandin F2alpha + NADH + H+
-
Substrates: -
Products: -
?
prostaglandin F2alpha + NAD+
15-ketoprostaglandin F2alpha + NADH + H+
-
Substrates: specific for NAD+
Products: -
?
prostaglandin F2alpha + NAD+
15-ketoprostaglandin F2alpha + NADH + H+
-
Substrates: -
Products: -
?
prostaglandin F2alpha + NAD+
15-ketoprostaglandin F2alpha + NADH + H+
-
Substrates: specific for NAD+
Products: -
?
prostaglandin F2alpha + NAD+
15-ketoprostaglandin F2alpha + NADH + H+
-
Substrates: NADP+ is more effective than NAD+
Products: -
?
prostaglandin F2alpha + NAD+
15-ketoprostaglandin F2alpha + NADH + H+
-
Substrates: -
Products: -
?
additional information
?
-
-
Substrates: the enzyme catalyzes specifically the oxidation of the (15S)-hydroxy group of all natural prostaglandins except the B and 19-hydroxylated types
Products: -
?
additional information
?
-
-
Substrates: dexamethasone and phorbol ester play a role in enzyme regulation in erythroleukemia cells
Products: -
?
additional information
?
-
-
Substrates: key enzyme for metabolic inactivation of prostaglandins, enzyme levels are reduced in inflammatory bowel disease involving TNF-alpha
Products: -
?
additional information
?
-
-
Substrates: the enzyme is a tumor suppressor of human breast cancer, expression of the enzyme and the estrogen receptor is correlated, silencing of the enzyme results in enhanced cancer cell proliferation, the enzyme expression is silenced in vivo in cancer cells due to promoter methylation
Products: -
?
additional information
?
-
-
Substrates: the enzyme is involved in anti-proliferative effect of non-steroidal anti-inflammatory drugs COX-1 inhibitors on a medullary thyroid carcinoma cell line
Products: -
?
additional information
?
-
-
Substrates: 15-hydroxyprostaglandin dehydrogenase may be repressed by an epigenetic mechanism involving histone deacetylation, resulting in increased prostaglandin E2 activity in tumors
Products: -
?
additional information
?
-
-
Substrates: prostaglandins play an essential role in primate parturition acting on uterine contractility and on cervical ripening
Products: -
?
additional information
?
-
-
Substrates: the enzyme is an in vivo suppressor of colon tumorigenesis, mechanism of conferring increased susceptibility to colon neoplasia, overview
Products: -
?
additional information
?
-
-
Substrates: the enzyme is an in vivo suppressor of colon tumorigenesis, mechanism of conferring increased susceptibility to colon neoplasia, overview
Products: -
?
additional information
?
-
-
Substrates: substrate specificity, overview, no activity with prostaglandin B1
Products: -
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
-
Substrates: -
Products: i.e. 15-hydroxyprostaglandin or (15S)-PGE2
r
(5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
15-hydroxyprostaglandin + NAD+
15-oxoprostaglandin + NADH + H+
-
Substrates: physiological inactivation of prostaglandin by catalyzing the first step in catabolism
Products: -
?
prostaglandin E2 + NAD+
15-oxoprostaglandin E2 + NADH + H+
additional information
?
-
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
Substrates: -
Products: -
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
Substrates: -
Products: -
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
Substrates: first step in prostaglandin catabolism
Products: -
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
Substrates: first step in prostaglandin catabolism
Products: -
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
Substrates: -
Products: -
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
Substrates: -
Products: -
r
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
Substrates: catabolism of (15S)-PGE2
Products: -
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
Substrates: first step in prostaglandin catabolism
Products: -
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
Substrates: first step in prostaglnadin catabolism
Products: -
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
Substrates: key step in prostaglandin catabolism, enzyme activation leads to reduced cell proliferation, the enzyme is an antagonist of ibuprofen
Products: -
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
Substrates: key step in prostaglandin inactivation
Products: -
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
Substrates: PGE2 degradation
Products: -
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
Substrates: prostaglandin E2, PGE2, a proinflammatory bioactive lipid, promotes cancer progression by modulating proliferation, apoptosis, and angiogenesis, PGE2 is a downstream product cyclooxygenase and is biochemically inactivated by the enzyme
Products: -
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
Substrates: reciprocal regulation of cyclooxygenase-2 and 15-hydroxyprostaglandin dehydrogenase expression in A549 human lung adenocarcinoma cells, overview
Products: -
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
Substrates: the enzyme is a putative cyclooxygenase-2 antagonist and and tumor suppressor
Products: -
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
Substrates: transcriptional regulation and biological functions, the enzyme cooperates with cyclooxygenase-2 to control cellular prostaglandin levels, reciprocal regulation of the two enzymes, overview
Products: -
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
Substrates: -
Products: -
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
Substrates: i.e. 15-hydroxyprostaglandin or (15S)-PGE2
Products: -
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
Substrates: PGE2 degradation
Products: -
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
Substrates: i.e. 15-hydroxyprostaglandin or (15S)-PGE2
Products: -
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
Substrates: first step in prostaglandin catabolism
Products: -
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
Substrates: first step in prostaglandin catabolism
Products: -
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
Substrates: first step in prostaglandin catabolism
Products: -
?
(5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
Substrates: -
Products: -
?
(5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
Substrates: -
Products: -
?
(5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
Substrates: the enzyme catalyzes the oxidation of the 15(S)-hydroxyl group of prostaglandin E2 (PGE2), converting the proinflammatory PGE2 to the anti-inflammatory 15-keto-PGE2 (an endogenous ligand for peroxisome proliferator-activated receptor-gamma [PPAR-gamma])
Products: -
?
(5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
Substrates: -
Products: -
?
prostaglandin E2 + NAD+
15-oxoprostaglandin E2 + NADH + H+
Substrates: -
Products: -
?
prostaglandin E2 + NAD+
15-oxoprostaglandin E2 + NADH + H+
-
Substrates: -
Products: -
?
prostaglandin E2 + NAD+
15-oxoprostaglandin E2 + NADH + H+
Substrates: -
Products: -
?
prostaglandin E2 + NAD+
15-oxoprostaglandin E2 + NADH + H+
-
Substrates: -
Products: -
?
additional information
?
-
-
Substrates: dexamethasone and phorbol ester play a role in enzyme regulation in erythroleukemia cells
Products: -
?
additional information
?
-
-
Substrates: key enzyme for metabolic inactivation of prostaglandins, enzyme levels are reduced in inflammatory bowel disease involving TNF-alpha
Products: -
?
additional information
?
-
-
Substrates: the enzyme is a tumor suppressor of human breast cancer, expression of the enzyme and the estrogen receptor is correlated, silencing of the enzyme results in enhanced cancer cell proliferation, the enzyme expression is silenced in vivo in cancer cells due to promoter methylation
Products: -
?
additional information
?
-
-
Substrates: the enzyme is involved in anti-proliferative effect of non-steroidal anti-inflammatory drugs COX-1 inhibitors on a medullary thyroid carcinoma cell line
Products: -
?
additional information
?
-
-
Substrates: 15-hydroxyprostaglandin dehydrogenase may be repressed by an epigenetic mechanism involving histone deacetylation, resulting in increased prostaglandin E2 activity in tumors
Products: -
?
additional information
?
-
-
Substrates: prostaglandins play an essential role in primate parturition acting on uterine contractility and on cervical ripening
Products: -
?
additional information
?
-
-
Substrates: the enzyme is an in vivo suppressor of colon tumorigenesis, mechanism of conferring increased susceptibility to colon neoplasia, overview
Products: -
?
additional information
?
-
-
Substrates: the enzyme is an in vivo suppressor of colon tumorigenesis, mechanism of conferring increased susceptibility to colon neoplasia, overview
Products: -
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(1-butyl-1H-benzimidazol-5-yl)(piperidin-1-yl)methanone
-
(1-phenyl-1H-benzimidazol-5-yl)(piperidin-1-yl)methanone
-
(1-tert-butyl-1H-benzimidazol-5-yl)(piperidin-1-yl)methanone
-
(3,3-dimethylpiperidin-1-yl)[1-(3-methylphenyl)-1H-benzimidazol-5-yl]methanone
-
(3,5-dimethylpiperidin-1-yl)[1-(3-methylphenyl)-1H-benzimidazol-5-yl]methanone
-
(4-([(4-chlorophenyl)sulfanyl]methyl)phenyl)(4-methylpiperidin-1-yl)methanone
-
-
(4-bromopiperidin-1-yl)[1-(3-methylphenyl)-1H-benzimidazol-5-yl]methanone
-
(4-[(2-bromophenoxy)methyl]phenyl)(piperidin-1-yl)methanone
-
-
(5Z)-5-[3-bromo-4-(2-cyclohexylethoxy)benzylidene]-1,3-thiazolidine-2,4-dione
-
-
(5Z)-5-[3-chloro-4-(2-cyclohexylethoxy)benzylidene]-1,3-thiazolidine-2,4-dione
-
-
(5Z)-5-[3-chloro-4-(3-cyclohexylpropoxy)benzylidene]-1,3-thiazolidine-2,4-dione
-
-
(5Z)-5-[3-chloro-4-(4-cyclohexylbutoxy)benzylidene]-1,3-thiazolidine-2,4-dione
-
-
(5Z)-5-[3-chloro-4-(cyclohexylmethoxy)benzylidene]-1,3-thiazolidine-2,4-dione
-
-
(5Z)-5-[3-chloro-4-(cyclohexyloxy)benzylidene]-1,3-thiazolidine-2,4-dione
-
-
(5Z)-5-[4-(2-cyclohexylethoxy)-3-methoxybenzylidene]-1,3-thiazolidine-2,4-dione
-
-
(5Z)-5-[4-(2-cyclohexylethoxy)-3-methoxybenzylidene]-3-methyl-1,3-thiazolidine-2,4-dione
-
-
(5Z)-5-[4-(2-cyclohexylethoxy)benzylidene]-1,3-thiazolidine-2,4-dione
-
-
(9Z,12E)-13-hydroxyoctadeca-9,12-dienoic acid
-
0.01 mM, 45% inhibition
(piperidin-1-yl)[1-[3-(propan-2-yl)phenyl]-1H-benzimidazol-5-yl]methanone
-
(piperidin-1-yl)[1-[3-(trifluoromethyl)phenyl]-1H-benzimidazol-5-yl]methanone
-
(piperidin-1-yl)[1-[4-(trifluoromethyl)phenyl]-1H-benzimidazol-5-yl]methanone
-
1,2-naphthoquinone
-
0.0002 mM, time dependent inactivation, 1 mM glutathione or 40% glycerol protect from inactivation; inactivation, glutathione protects
12-O-tetradecanoylphorbol-13-acetate
-
10 nM, rapid loss of activity in eryrthroleukemia cells during 40 min, inhibition can be prevented by staurosporin indicating that protein kinase C is involved; induces the synthesis of 15-PGDH but inhibits the enzyme activity a protein kinase C mediated mechanism
13-cis-Prostaglandin F2alpha
-
0.124 mM, 50% inhibition
13-hydroxyperoxyoctadecadienoic acid
-
0.001 mM to 0.01 mM, 50% inhibition with 0.003 mM, uncompetitive inhibition vs. NAD+, noncompetitive vs. prostaglandin E2
15-deoxy-DELTA12,14-prostaglandin J2
-
0.024 mM, 50% inhibition
15-epi-prostaglandin E1
-
-
15-Epiprostaglandin E1
-
0.17 mM, 50% inhibition
15-ketoprostaglandin E1
-
-
15-ketoprostaglandin E2
-
-
2,4,6-Trinitrobenzenesulfonic acid
-
-
2-([(6-bromo-4H-imidazo[4,5-b]pyridin-2-yl)sulfanyl]methyl)benzonitrile
-
-
2-azido NAD+
-
photoaffinity analog of NAD+, 0.115 mM, complete inactivation
2-hydroxy-5-(3,5-dimethoxycarbonyl-benzoyl)-benzene acetic acid
2-methyl-1,4-naphthoquinone
-
0.02 mM, time dependent inactivation
2-[[(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)sulfanyl]methyl]benzonitrile
-
3,3',5-triiodothyronine
-
-
3-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)-5,6,7,8,9,10-hexahydro[1,2,4]triazolo[4,3-a]azocine
-
3-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridine
-
3-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)-6,7,8,9,10,11-hexahydro-5H-[1,2,4]triazolo[4,3-a]azonine
-
3-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)-6,7,8,9-tetrahydro-5H-pyrrolo[1,2-a]azepine
-
3-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
-
-
3-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazole
-
3-[1-(3,4-dichlorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
-
3-[1-(3-chlorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
-
3-[1-(4-bromophenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
-
3-[1-(4-chlorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
-
3-[1-(4-fluorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
-
3-[1-(4-methoxyphenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
-
3-[1-(4-tert-butylphenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
-
3-[2,5-dimethyl-1-(4-methylphenyl)-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
-
3-[2,5-dimethyl-1-(4-nitrophenyl)-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
-
3-[2,5-dimethyl-1-[3-(trifluoromethyl)phenyl]-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
-
3-[2,5-dimethyl-1-[4-(naphthalen-2-yl)phenyl]-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
-
3-[2,5-dimethyl-1-[4-(pyridin-2-yl)phenyl]-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
-
3-[2,5-dimethyl-1-[4-(pyridin-3-yl)phenyl]-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
-
3-[2,5-dimethyl-1-[4-(pyridin-4-yl)phenyl]-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
-
3-[2,5-dimethyl-1-[4-(trifluoromethyl)phenyl]-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
-
3-[2,5-dimethyl-3-(6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepin-3-yl)-1H-pyrrol-1-yl]benzonitrile
-
4,5-benzo[a]pyrenequinone
-
0.0002 mM, time dependent inactivation
4-((2,5-dioxopyrrolidin-3-ylidene)methyl)phenylthiophene-2-carboxylate
-
4-chloromercuriphenylsulfonic acid
-
-
4-methoxybenzyl-2,4-thiazolidinedione
-
-
4-methoxybenzylidene-2,4-thiazolidinedione
-
-
4-[2,5-dimethyl-3-(6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepin-3-yl)-1H-pyrrol-1-yl]benzonitrile
-
5-(2-chloro-3-(2-(pyridin-2-yl)ethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
-
5-(2-chloro-4-(2-(cyclohexyloxy)ethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
-
5-(2-chloro-4-(2-(propan-2-yloxy)ethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
-
5-(2-chloro-4-(2-cyclohexylethoxy)benzylidene)-thiazolidine-2,4-dione
-
5-(2-chloro-4-(2-cyclopentylethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
-
5-(2-chloro-4-(4-nitrobenzyloxy)benzylidene)thiazolidine-2,4-dione
-
5-(2-chloro-4-phenbutoxybenzylidene)thiazolidine-2,4-dione
-
5-(2-chloro-4-phenethoxybenzylidene)thiazolidine-2,4-dione
-
5-(2-chloro-4-phenpropoxybenzylidene)thiazolidine-2,4-dione
-
5-(3-chloro-4-((4-(prop-1-en-2-yl)cyclohexyl)methoxy)benzylidene)-1,3-thiazolidine-2,4-dione
-
5-(3-chloro-4-((5-oxo-5,6,7,8-tetrahydronaphthalen-1-yl)oxy)benzylidene)-1,3-thiazolidine-2,4-dione
-
5-(3-chloro-4-(2-(4-methyl-1,3-thiazolidin-5-yl)ethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
-
5-(3-chloro-4-(2-(5-ethylpyridin-2-yl)ethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
-
5-(3-chloro-4-(2-(5-nitrofuran-2-yl)ethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
-
5-(3-chloro-4-(2-(cyclohexyloxy)ethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
-
5-(3-chloro-4-(2-(propan-2-yloxy)ethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
-
5-(3-chloro-4-(2-(pyridin-2-yl)ethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
-
5-(3-chloro-4-(2-(thiophen-2-yl)ethoxy)benzylidene)thiazolidine-2,4-dione
-
5-(3-chloro-4-(2-cyclopentylethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
-
5-(3-chloro-4-(2-cyclopropylpropyl)benzylidene)-1,3-thiazolidine-2,4-dione
-
5-(3-chloro-4-(2-thiomorpholine 1,1-dioxideethoxy)benzylidene)thiazolidine-2,4-dione
-
5-(3-chloro-4-(3-(2-nitroethenyl)phenoxy)benzylidene)-1,3-thiazolidine-2,4-dione
-
5-(3-chloro-4-(3-nitrophenoxy)benzylidene)-1,3-thiazolidine-2,4-dione
-
5-(3-chloro-4-(3-phenylpropoxy)benzylidene)thiazolidine-2,4-dione
-
5-(3-chloro-4-(4-nitrobenzyloxy)benzylidene)thiazolidine-2,4-dione
-
5-(3-chloro-4-(4-phenylbutoxy)benzylidene)thiazolidine-2,4-dione
-
5-(3-chloro-4-(cyclobutylmethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
-
5-(3-chloro-4-(cyclopentylmethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
-
5-(3-chloro-4-phenylethoxybenzylidene)thiazolidine-2,4-dione
-
5-(4-((4-methylcyclohexyl)methoxy)benzylidene) thiazolidine-2,4-dione
-
-
5-(4-(1,3-benzodioxol-5-ylmethoxy)-3-chlorobenzylidene)-1,3-thiazolidine-2,4-dione
-
5-(4-(2-(thiophen-2-yl)ethoxy)benzylidene)thiazolidine-2,4-dione
-
-
5-(4-(2-(thiophen-3-yl)ethoxy)benzylidene)thiazolidine-2,4-dione
-
-
5-(4-(2-cyclopentylethoxy)benzylidene)thiazolidine-2,4-dione
-
-
5-(4-(4-(chloromethyl)benzyloxy)benzylidene) thiazolidine-2,4-dione
-
-
5-(4-(benzyloxy)-2-chlorobenzylidene)thiazolidine-2,4-dione
-
5-(4-(benzyloxy)-3-chlorobenzylidene)thiazolidine-2,4-dione
-
5-(4-(bicyclo[2.2.1]hept-2-ylmethoxy)-3-chlorobenzylidene)-1,3-thiazolidine-2,4-dione
-
5-(4-(cyclopentylmethoxy)benzylidene)thiazolidine-2,4-dione
-
-
5-[4-((1-methyl)-cyclohexylmethoxy)benzylidene]-2,4-thiazolidenedione
-
-
5-[4-((1-methyl)-cyclohexylmethoxy)benzyl]-2,4-thiazolidenedione
-
trivial name ciglitazone
5-[4-(benzoxy)benzylidene]-2,4-thiazolidenedione
-
-
5-[4-(cyclohexylbutoxy)benzylidene]-2,4-thiazolidenedione
-
-
5-[4-(cyclohexylethoxy)benzylidene]-2,4-thiazolidenedione
-
-
5-[4-(cyclohexylmethoxy)benzylidene]-2,4-thiazolidenedione
-
-
5-[4-(cyclohexyloxy)benzylidene]-2,4-thiazolidenedione
-
-
5-[4-(cyclohexylpropoxy)benzylidene]-2,4-thiazolidenedione
-
-
5-[[4-(ethoxycarbonyl)phenyl]azo]-2-hydroxy-benzeneacetic acid
-
CAY-10397, specific 15-PGDH inhibitor
5-[[4-(ethoxycarbonyl)phenyl]azo]2-hydroxy-benzene acetic acid
CAY-10397
7,8-benzo[a]pyrenequinone
-
0.0002 mM, time dependent inactivation, 40% glycerol protects from inactivation; inactivation, glutathione protects
7-Oxa-13-prostynoic acid
-
0.0475 mM, 50% inhibition
7-oxa-prostanoic acid
-
-
7-Thia-13-prostynoic acid
-
0.0068 mM, 50% inhibition
7-thia-prostanoic acid
-
-
acrolein
-
irreversible inhibition
adenosine-5'-diphosphoribose
-
-
Berberine
-
0.023 mM, 50% inhibition
Biochanin A
-
0.031 mM, 50% inhibition
CAY 10397
-
specific inhibitor, completely reverses the stimulating effect of ibuprofen on cell proliferation in TT cells
chalcone
-
0.016 mM, 50% inhibition
chrysin
-
0.021 mM, 50% inhibition
Cu2+
-
0.05 mM to 0.5 mM, 50% inhibition with 0.1 mM, uncompetitive vs. NAD+, non-competitive vs. prostaglandin E2
curcumin
-
0.01 mM, 50% inhibition
DuP 697
-
0.022 mM, 50% inhibition
ent-13-dehydro-15-epi-prostaglandin F2alpha
-
-
Ent-13-dehydro-15-epiprostaglandin F3alpha
-
0.055 mM, 50% inhibition
ent-13-dehydroprostaglandin E2
-
0.0068 mM, 50% inhibition
epi-7-thia-prostaglandin F2alpha
-
-
epi-7-thiaprostaglandin F2alpha
-
0.0052 mM, 50% inhibition
epigallocatechin gallate
-
0.012 mM, 50% inhibition
ethyl 4-[2,5-dimethyl-3-(6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepin-3-yl)-1H-pyrrol-1-yl]benzoate
-
Flufenamic acid
-
0.041 mM, 50% inhibition
flurbiprofen
-
0.062 mM, 50% inhibition
glycerol
-
slight inhibition
hexadecanoic acid
-
0.01 mM
ketorolac
-
0.028 mM, 50% inhibition
linoleic acid
-
0.01 mM, 30% inhibition
Meclofenamic acid
-
0.073 mM, 50% inhibition
Mefenamic acid
-
0.076 mM, 50% inhibition
mixture of endogenous fatty acids
-
mixture contains palmitic acid, stearic acid linoleic acid and oleic acid, competitive vs. prostaglandine E2
-
MK 886
-
0.037 mM, 50% inhibition
N,N-diethyl-1-(3-methylphenyl)-1H-benzimidazole-5-carboxamide
-
N-(2-phenylethyl)-indomethacin amide
-
0.098 mM, 50% inhibition
N-(3-pyridyl)-indomethacin amide
-
0.1 mM, 50% inhibition
N-butyl-1-(3-methylphenyl)-1H-benzimidazole-5-carboxamide
-
N-cyclopentyl-1-(3-methylphenyl)-1H-benzimidazole-5-carboxamide
-
nat-13-dehydroprostaglandin E2
-
-
nat-13-dehydroprostaglandin F3alpha
-
-
Nat-13-thiaprostaglandin F2alpha
-
0.0088 mM, 50% inhibition
-
nat-7-thia-prostaglandin F2alpha
-
-
nat-l3-dehydroprostaglandin F2alpha
-
-
niflumic acid
-
0.058 mM, 50% inhibition
nimesulide
-
0.051 mM, 50% inhibition
NS 398
-
0.064 mM, 50% inhibition
octadecanoic acid
-
0.01 mM
p-chloromercuriphenylsulfonic acid
-
-
PD 98059
-
an ERK kinase inhibitor
prostaglandin F2alpha
-
-
pyridoxal 5'-phosphate
-
-
resveratrol
-
0.054 mM, 50% inhibition
sulindac
-
0.041 mM, 50% inhibition
sulindac sulfide
-
0.018 mM, 50% inhibition
sulindac sulfone
-
0.038 mM, 50% inhibition
tetradecanoic acid
-
0.01 mM
Tetraiodothyroacetic acid
-
-
Zn2+
-
0.05 mM to 0.5 mM, 50% inhibition with 0.15 mM, uncompetitive vs. NAD+, non-competitive vs. prostaglandin E2
[1-(2-methoxyphenyl)-1H-benzimidazol-5-yl](piperidin-1-yl)methanone
-
[1-(3-chlorophenyl)-1H-benzimidazol-5-yl](piperidin-1-yl)methanone
-
[1-(3-methoxyphenyl)-1H-benzimidazol-5-yl](piperidin-1-yl)methanone
-
[1-(3-methylphenyl)-1H-benzimidazol-5-yl](3-methylpiperidin-1-yl)methanone
-
[1-(3-methylphenyl)-1H-benzimidazol-5-yl](3-phenylpiperidin-1-yl)methanone
-
[1-(3-methylphenyl)-1H-benzimidazol-5-yl](4-methylpiperazin-1-yl)methanone
-
[1-(3-methylphenyl)-1H-benzimidazol-5-yl](morpholin-4-yl)methanone
-
[1-(3-methylphenyl)-1H-benzimidazol-5-yl](piperidin-1-yl)methanone
[1-(3-methylphenyl)-1H-benzimidazol-5-yl](pyrrolidin-1-yl)methanone
-
[1-(3-methylphenyl)-1H-benzimidazol-5-yl][3-(propan-2-yl)piperidin-1-yl]methanone
-
[1-(3-methylphenyl)-1H-benzimidazol-5-yl][3-(trifluoromethyl)piperidin-1-yl]methanone
-
[1-(3-methylphenyl)-1H-benzimidazol-5-yl][4-(trifluoromethyl)piperidin-1-yl]methanone
-
[1-(3-tert-butylphenyl)-1H-benzimidazol-5-yl](piperidin-1-yl)methanone
-
[1-(4-chlorophenyl)-1H-benzimidazol-5-yl](piperidin-1-yl)methanone
-
[1-(4-methoxyphenyl)-1H-benzimidazol-5-yl](piperidin-1-yl)methanone
-
[1-(4-methylphenyl)-1H-benzimidazol-5-yl](piperidin-1-yl)methanone
-
[1-(4-tert-butylphenyl)-1H-benzimidazol-5-yl](piperidin-1-yl)methanone
-
[4-(4-methoxyphenyl)piperazin-1-yl](4-[(phenylsulfanyl)methyl]phenyl)methanone
-
-
2-hydroxy-5-(3,5-dimethoxycarbonyl-benzoyl)-benzene acetic acid
-
1000 times more potent inhibitor than sulfaphasalazine
2-hydroxy-5-(3,5-dimethoxycarbonyl-benzoyl)-benzene acetic acid
-
1000 times more potent inhibitor than sulfaphasalazine
arachidonic acid
-
0.0027 mM, 50% inhibition; irreversible inactivation
ciglitazone
-
-
ciglitazone
-
0.003 mM, 50% inhibition
Ethacrynic acid
-
0.0055 mM, 50% inhibition; irreversible inactivation
ethanol
-
slight inhibition
indomethacin
-
-
indomethacin
-
0.066 mM, 50% inhibition
N-ethylmaleimide
-
-
NAD+
-
-
NAD+
-
product inhibition
NADH
-
-
NADPH
-
-
papaverine
-
the inhibition is noncompetitive with prostaglandin E2, uncompetitive with NAD+, and reversible
papaverine
-
the inhibition is noncompetitive with prostaglandin E2, uncompetitive with NAD+, and reversible
papaverine
-
the inhibition is noncompetitive with prostaglandin E2, uncompetitive with NAD+, and reversible
papaverine
-
the inhibition is noncompetitive with prostaglandin E2, uncompetitive with NAD+, and reversible
Prostaglandin B1
-
0.0497 mM, 50% inhibition
prostaglandin E2
-
-
prostaglandin E2
-
product inhibition
Prostanoic acid
-
0.013 mM, 50% inhibition
rosiglitazone
-
-
rosiglitazone
-
0.026 mM, 50% inhibition
sulphasalazine
-
anticolitic drug
sulphasalazine
-
anticolitic drug
thyroxine
-
-
troglitazone
-
-
troglitazone
-
0.34 mM, 50% inhibition
[1-(3-methylphenyl)-1H-benzimidazol-5-yl](piperidin-1-yl)methanone
-
-
[1-(3-methylphenyl)-1H-benzimidazol-5-yl](piperidin-1-yl)methanone
-
additional information
-
no inhibition by Ca2+
-
additional information
-
not inhibited by L-thyronine and NADH
-
additional information
-
-
-
additional information
-
IC50 values at pH 7.0 and at pH 9.0; pH-dependent inhibition and inhibition mechanism, at high substrate concentrations there is formation of unreactive complexes between the 15-hydroxyrostaglandin and both the free enzyme and enzyme-NADH complex and between the 15-ketoprostaglandin and both the free enzyme and enzyme NAD+ complex
-
additional information
-
not inhibitited by iodoacetimide
-
additional information
-
TNF-alpha suppresses the enzyme expression in colonocytes
-
additional information
-
histone deacetylase inhibitors, such as sodium butyrate, scriptaid, apicidin, and oxamflatin, and transforming growth factor-beta, TGF-beta1, induce enzyme expression in lung adenocarcinoma cells, overview
-
additional information
-
the enzyme expression is suppressed by the epidermal growth factor via snail which interacts through its zinc finger structure, mechanism overview
-
additional information
-
enzyme down-regulation by estrogen
-
additional information
-
interleukin-1beta suppresses the enzyme expression, as well as down-regulation of cyclooxygenase-2 expression, whereas down-regulation of cyclooxygenase-1 has no effect on 15-PGDH expression, overview
-
additional information
-
bile acids activate the signal transduction pathway protein kinase C-> extracellular signal-regulated kinase 1/2-> early growth response factor-1-> Snail and thereby suppress 15-PGDH transcription, unconjugated bile acids are much more potent inhibitors of 15-PGDH expression and activity than related conjugated bile acids, chenodeoxycholate and deoxycholate suppress the transcription of 15-PGDH resulting in reduced amounts of mRNA, protein, and enzyme activity
-
additional information
-
histone deacetylase 2 and the transcriptional regulator Snail play a central role in the suppression of 15-PGDH expression
-
additional information
-
not inhibited by 10 mM to 80 mM ethanol
-
additional information
-
not inhibited by thyroid hormones and NADPH
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.0012 - 0.026
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate
0.00765 - 0.012
(5Z,8E,10E,12S)-12-hydroxy-5,8,10-heptadecatrienoic acid
0.016
15-hydroxyeicosatetraenoic acid
-
-
0.0521
15-ketoprostaglandin E1
-
at pH 7.0
0.0266 - 0.0528
15-ketoprostaglandin E2
0.077
19-hydroxyprostaglandin E1
-
-
0.283
20-hydroxyprostaglandin E1
-
-
0.066
6-ketoprostaglandin E1
-
-
0.111
6-ketoprostaglandin F1alpha
-
-
0.063
6-oxo-prostaglandin F1alpha
-
recombinant enzyme expressed in E. coli
0.0045 - 0.038
prostaglandin A1
0.003 - 0.022
Prostaglandin A2
0.741
Prostaglandin D2
-
-
0.0013 - 0.033
prostaglandin E1
0.00158 - 0.059
prostaglandin E2
0.077
prostaglandin E3
-
-
0.0213 - 0.133
prostaglandin F2alpha
additional information
additional information
-
Michaelis-Menten kinetics, overview
-
0.0012
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate
-
37°C, pH 7.5, I17L mutant
0.0026
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate
-
37°C, pH 7.5, N91D mutant
0.0034
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate
-
37°C, pH 7.5
0.0035
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate
-
37°C, pH 7.5, V186K mutant
0.0039
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate
-
-
0.0045
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate
-
37°C, pH 7.5, V186A mutant
0.006
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate
-
37°C, pH 7.5, N91A mutant
0.0063
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate
-
37°C, pH 7.5
0.0071
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate
-
37°C, pH 7.5
0.0086
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate
-
37°C, pH 7.5, T11S mutant
0.01
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate
-
pH 7.4, 37°C
0.011
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate
-
37°C, pH 7.5, I17A mutant
0.011
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate
-
37°C, pH 7.5, I17V mutant
0.013
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate
-
37°C, pH 7.5, Q15K/W37K double mutant
0.022
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate
-
37°C, pH 7.5, V186I mutant
0.026
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate
-
37°C, pH 7.5, Q15K mutant
0.00765
(5Z,8E,10E,12S)-12-hydroxy-5,8,10-heptadecatrienoic acid
-
-
0.012
(5Z,8E,10E,12S)-12-hydroxy-5,8,10-heptadecatrienoic acid
-
-
0.0266
15-ketoprostaglandin E2
-
at pH 9.0
0.0528
15-ketoprostaglandin E2
-
at pH 7.0
0.022
NAD+
-
recombinant enzyme expressed in E. coli
0.022
NAD+
-
37°C, pH 7.5, V186K mutant
0.0227
NAD+
-
at pH 9.0, + prostaglandin E2
0.024
NAD+
-
37°C, pH 7.5, V186A mutant
0.0284
NAD+
-
at pH 7.0, + prostaglandin E2
0.029
NAD+
-
at pH 9.0, + prostaglandin E1
0.0308
NAD+
-
at pH 7.0, + prostaglandin E1
0.032
NAD+
-
37°C, pH 7.5
0.032
NAD+
-
37°C, pH 7.5, N91D mutant
0.038
NAD+
-
37°C, pH 7.5
0.0399
NAD+
-
+ prostaglandin F2alpha
0.0405
NAD+
-
+ prostaglandin E2
0.0451
NAD+
-
+ prostaglandin E1
0.059
NAD+
-
37°C, pH 7.5, I17L mutant
0.098
NAD+
-
37°C, pH 7.5, I17V mutant
0.27
NAD+
-
37°C, pH 7.5, V186I mutant
0.55
NAD+
-
37°C, pH 7.5, I17A mutant
0.7
NAD+
-
37°C, pH 7.5, T11S mutant
0.72
NAD+
-
37°C, pH 7.5, N91A mutant
0.0156
NADH
-
at pH 7.0, + 15-keto-PGE1
0.0156
NADH
-
at pH 7.0, + 15-ketoprostaglandin E2
0.0594
NADH
-
at pH 9.0, + 15-ketoprostaglandin E2
0.0045
prostaglandin A1
-
recombinant enzyme expressed in E. coli
0.033
prostaglandin A1
-
-
0.038
prostaglandin A1
-
-
0.003
Prostaglandin A2
-
-
0.022
Prostaglandin A2
-
recombinant enzyme expressed in E. coli
0.0013
prostaglandin E1
-
-
0.0013
prostaglandin E1
-
at pH 7.0
0.0034
prostaglandin E1
-
-
0.0048
prostaglandin E1
-
-
0.0048
prostaglandin E1
-
at pH 9.0
0.005
prostaglandin E1
-
recombinant enzyme expressed in E. coli
0.0054
prostaglandin E1
-
-
0.027
prostaglandin E1
-
-
0.033
prostaglandin E1
-
-
0.033
prostaglandin E1
-
pH 10.2
0.00158
prostaglandin E2
-
-
0.0025
prostaglandin E2
-
at pH 7.0
0.0026
prostaglandin E2
-
-
0.0028
prostaglandin E2
-
at pH 9.0
0.0028
prostaglandin E2
-
pH 8.0, 25°C, 20 nM [1-(3-methylphenyl)-1H-benzimidazol-5-yl](piperidin-1-yl)methanone
0.0037
prostaglandin E2
-
pH 8.0, 25°C, 10 nM [1-(3-methylphenyl)-1H-benzimidazol-5-yl](piperidin-1-yl)methanone
0.0039
prostaglandin E2
-
recombinant enzyme expressed in E. coli
0.0055
prostaglandin E2
-
pH 8.0, 25°C
0.0056
prostaglandin E2
-
pH 8.0, 25°C, 4 nM 3-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
0.0064
prostaglandin E2
-
pH 8.0, 25°C, 10 nM 3-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
0.0075
prostaglandin E2
-
pH 8.0, 25°C, 10 nM 2-([(6-bromo-4H-imidazo[4,5-b]pyridin-2-yl)sulfanyl]methyl)benzonitrile
0.01
prostaglandin E2
-
-
0.0117
prostaglandin E2
-
-
0.0135
prostaglandin E2
-
pH 8.0, 25°C, 10 nM 2-([(6-bromo-4H-imidazo[4,5-b]pyridin-2-yl)sulfanyl]methyl)benzonitrile
0.014
prostaglandin E2
-
-
0.059
prostaglandin E2
-
-
0.059
prostaglandin E2
-
pH 10.2
0.0213
prostaglandin F2alpha
-
-
0.025
prostaglandin F2alpha
-
-
0.04
prostaglandin F2alpha
-
recombinant enzyme expressed in E. coli
0.059
prostaglandin F2alpha
-
-
0.133
prostaglandin F2alpha
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.000068
(1-butyl-1H-benzimidazol-5-yl)(piperidin-1-yl)methanone
Homo sapiens
pH and temperature not specified in the publication
0.000022
(1-phenyl-1H-benzimidazol-5-yl)(piperidin-1-yl)methanone
Homo sapiens
pH and temperature not specified in the publication
0.000034
(1-tert-butyl-1H-benzimidazol-5-yl)(piperidin-1-yl)methanone
Homo sapiens
pH and temperature not specified in the publication
0.000068
(3,3-dimethylpiperidin-1-yl)[1-(3-methylphenyl)-1H-benzimidazol-5-yl]methanone
Homo sapiens
pH and temperature not specified in the publication
0.000271
(3,5-dimethylpiperidin-1-yl)[1-(3-methylphenyl)-1H-benzimidazol-5-yl]methanone
Homo sapiens
pH and temperature not specified in the publication
0.000631
(4-([(4-chlorophenyl)sulfanyl]methyl)phenyl)(4-methylpiperidin-1-yl)methanone
Homo sapiens
-
pH 8, 25°C
0.000076
(4-bromopiperidin-1-yl)[1-(3-methylphenyl)-1H-benzimidazol-5-yl]methanone
Homo sapiens
pH and temperature not specified in the publication
0.000089
(4-[(2-bromophenoxy)methyl]phenyl)(piperidin-1-yl)methanone
Homo sapiens
-
pH 8, 25°C
0.000019
(5Z)-5-[3-bromo-4-(2-cyclohexylethoxy)benzylidene]-1,3-thiazolidine-2,4-dione
Homo sapiens
-
pH and temperature not specified in the publication
0.000008
(5Z)-5-[3-chloro-4-(2-cyclohexylethoxy)benzylidene]-1,3-thiazolidine-2,4-dione
Homo sapiens
-
pH and temperature not specified in the publication
0.00001
(5Z)-5-[3-chloro-4-(3-cyclohexylpropoxy)benzylidene]-1,3-thiazolidine-2,4-dione
Homo sapiens
-
pH and temperature not specified in the publication
0.000024
(5Z)-5-[3-chloro-4-(4-cyclohexylbutoxy)benzylidene]-1,3-thiazolidine-2,4-dione
Homo sapiens
-
pH and temperature not specified in the publication
0.000028
(5Z)-5-[3-chloro-4-(cyclohexylmethoxy)benzylidene]-1,3-thiazolidine-2,4-dione
Homo sapiens
-
pH and temperature not specified in the publication
0.000047
(5Z)-5-[3-chloro-4-(cyclohexyloxy)benzylidene]-1,3-thiazolidine-2,4-dione
Homo sapiens
-
pH and temperature not specified in the publication
0.000025
(5Z)-5-[4-(2-cyclohexylethoxy)-3-methoxybenzylidene]-1,3-thiazolidine-2,4-dione
Homo sapiens
-
pH and temperature not specified in the publication
0.05
(5Z)-5-[4-(2-cyclohexylethoxy)-3-methoxybenzylidene]-3-methyl-1,3-thiazolidine-2,4-dione
Homo sapiens
-
pH and temperature not specified in the publication
0.000051
(5Z)-5-[4-(2-cyclohexylethoxy)benzylidene]-1,3-thiazolidine-2,4-dione
Homo sapiens
-
pH and temperature not specified in the publication
0.000068
(piperidin-1-yl)[1-[3-(propan-2-yl)phenyl]-1H-benzimidazol-5-yl]methanone
Homo sapiens
pH and temperature not specified in the publication
0.000048
(piperidin-1-yl)[1-[3-(trifluoromethyl)phenyl]-1H-benzimidazol-5-yl]methanone
Homo sapiens
pH and temperature not specified in the publication
0.00086
(piperidin-1-yl)[1-[4-(trifluoromethyl)phenyl]-1H-benzimidazol-5-yl]methanone
Homo sapiens
pH and temperature not specified in the publication
0.000141
2-([(6-bromo-4H-imidazo[4,5-b]pyridin-2-yl)sulfanyl]methyl)benzonitrile
Homo sapiens
-
pH 8, 25°C
0.000242
3-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)-5,6,7,8,9,10-hexahydro[1,2,4]triazolo[4,3-a]azocine
Homo sapiens
pH and temperature not specified in the publication
0.000192
3-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridine
Homo sapiens
pH and temperature not specified in the publication
0.000383
3-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)-6,7,8,9,10,11-hexahydro-5H-[1,2,4]triazolo[4,3-a]azonine
Homo sapiens
pH and temperature not specified in the publication
0.000054
3-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)-6,7,8,9-tetrahydro-5H-pyrrolo[1,2-a]azepine
Homo sapiens
pH and temperature not specified in the publication
0.00089
3-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
Homo sapiens
-
pH 8, 25°C
0.00304
3-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazole
Homo sapiens
pH and temperature not specified in the publication
0.000022
3-[1-(3,4-dichlorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
Homo sapiens
pH and temperature not specified in the publication
0.000034
3-[1-(3-chlorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
Homo sapiens
pH and temperature not specified in the publication
0.000048
3-[1-(4-bromophenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
Homo sapiens
pH and temperature not specified in the publication
0.000038
3-[1-(4-chlorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
Homo sapiens
pH and temperature not specified in the publication
0.000121
3-[1-(4-fluorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
Homo sapiens
pH and temperature not specified in the publication
0.000086
3-[1-(4-methoxyphenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
Homo sapiens
pH and temperature not specified in the publication
0.000136
3-[1-(4-tert-butylphenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
Homo sapiens
pH and temperature not specified in the publication
0.000034
3-[2,5-dimethyl-1-(4-methylphenyl)-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
Homo sapiens
pH and temperature not specified in the publication
0.000108
3-[2,5-dimethyl-1-(4-nitrophenyl)-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
Homo sapiens
pH and temperature not specified in the publication
0.000048
3-[2,5-dimethyl-1-[3-(trifluoromethyl)phenyl]-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
Homo sapiens
pH and temperature not specified in the publication
0.000108
3-[2,5-dimethyl-1-[4-(naphthalen-2-yl)phenyl]-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
Homo sapiens
pH and temperature not specified in the publication
0.001078
3-[2,5-dimethyl-1-[4-(pyridin-2-yl)phenyl]-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
Homo sapiens
pH and temperature not specified in the publication
0.000271
3-[2,5-dimethyl-1-[4-(pyridin-3-yl)phenyl]-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
Homo sapiens
pH and temperature not specified in the publication
0.000383
3-[2,5-dimethyl-1-[4-(pyridin-4-yl)phenyl]-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
Homo sapiens
pH and temperature not specified in the publication
0.000068
3-[2,5-dimethyl-1-[4-(trifluoromethyl)phenyl]-1H-pyrrol-3-yl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
Homo sapiens
pH and temperature not specified in the publication
0.000076
3-[2,5-dimethyl-3-(6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepin-3-yl)-1H-pyrrol-1-yl]benzonitrile
Homo sapiens
pH and temperature not specified in the publication
0.000264
4-((2,5-dioxopyrrolidin-3-ylidene)methyl)phenylthiophene-2-carboxylate
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.000096
4-[2,5-dimethyl-3-(6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepin-3-yl)-1H-pyrrol-1-yl]benzonitrile
Homo sapiens
pH and temperature not specified in the publication
0.008915
5-(2-chloro-3-(2-(pyridin-2-yl)ethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.000211
5-(2-chloro-4-(2-(cyclohexyloxy)ethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.00105
5-(2-chloro-4-(2-(propan-2-yloxy)ethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.000013
5-(2-chloro-4-(2-cyclohexylethoxy)benzylidene)-thiazolidine-2,4-dione
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.000042
5-(2-chloro-4-(2-cyclopentylethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.00454
5-(2-chloro-4-(4-nitrobenzyloxy)benzylidene)thiazolidine-2,4-dione
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.000081
5-(2-chloro-4-phenbutoxybenzylidene)thiazolidine-2,4-dione
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.000178
5-(2-chloro-4-phenethoxybenzylidene)thiazolidine-2,4-dione
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.000052
5-(2-chloro-4-phenpropoxybenzylidene)thiazolidine-2,4-dione
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.000075
5-(3-chloro-4-((4-(prop-1-en-2-yl)cyclohexyl)methoxy)benzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.000071
5-(3-chloro-4-((5-oxo-5,6,7,8-tetrahydronaphthalen-1-yl)oxy)benzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.005165
5-(3-chloro-4-(2-(4-methyl-1,3-thiazolidin-5-yl)ethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.002077
5-(3-chloro-4-(2-(5-ethylpyridin-2-yl)ethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.000123
5-(3-chloro-4-(2-(5-nitrofuran-2-yl)ethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.00002
5-(3-chloro-4-(2-(cyclohexyloxy)ethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.002738
5-(3-chloro-4-(2-(propan-2-yloxy)ethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.00444
5-(3-chloro-4-(2-(pyridin-2-yl)ethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.000084
5-(3-chloro-4-(2-(thiophen-2-yl)ethoxy)benzylidene)thiazolidine-2,4-dione
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.000099
5-(3-chloro-4-(2-cyclopentylethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.000132
5-(3-chloro-4-(2-cyclopropylpropyl)benzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.000223
5-(3-chloro-4-(2-thiomorpholine 1,1-dioxideethoxy)benzylidene)thiazolidine-2,4-dione
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.000059
5-(3-chloro-4-(3-(2-nitroethenyl)phenoxy)benzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.0001
5-(3-chloro-4-(3-nitrophenoxy)benzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.000038
5-(3-chloro-4-(3-phenylpropoxy)benzylidene)thiazolidine-2,4-dione
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.00093
5-(3-chloro-4-(4-nitrobenzyloxy)benzylidene)thiazolidine-2,4-dione
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.000048
5-(3-chloro-4-(4-phenylbutoxy)benzylidene)thiazolidine-2,4-dione
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.000009
5-(3-chloro-4-(cyclobutylmethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.000011
5-(3-chloro-4-(cyclopentylmethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.00002
5-(3-chloro-4-phenylethoxybenzylidene)thiazolidine-2,4-dione
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.000052
5-(4-((4-methylcyclohexyl)methoxy)benzylidene) thiazolidine-2,4-dione
Homo sapiens
-
pH 7.5, temperature not specified in the publication
0.000193
5-(4-(1,3-benzodioxol-5-ylmethoxy)-3-chlorobenzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.000031
5-(4-(2-(thiophen-2-yl)ethoxy)benzylidene)thiazolidine-2,4-dione
Homo sapiens
-
pH 7.5, temperature not specified in the publication
0.00006
5-(4-(2-(thiophen-3-yl)ethoxy)benzylidene)thiazolidine-2,4-dione
Homo sapiens
-
pH 7.5, temperature not specified in the publication
0.000116
5-(4-(2-cyclopentylethoxy)benzylidene)thiazolidine-2,4-dione
Homo sapiens
-
pH 7.5, temperature not specified in the publication
0.000124
5-(4-(4-(chloromethyl)benzyloxy)benzylidene) thiazolidine-2,4-dione
Homo sapiens
-
pH 7.5, temperature not specified in the publication
0.000487
5-(4-(benzyloxy)-2-chlorobenzylidene)thiazolidine-2,4-dione
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.000048
5-(4-(benzyloxy)-3-chlorobenzylidene)thiazolidine-2,4-dione
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.000165
5-(4-(bicyclo[2.2.1]hept-2-ylmethoxy)-3-chlorobenzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.000045
5-(4-(cyclopentylmethoxy)benzylidene)thiazolidine-2,4-dione
Homo sapiens
-
pH 7.5, temperature not specified in the publication
0.000051
CT-8
Homo sapiens
at pH 7.5, temperature not specified in the publication
0.000038
ethyl 4-[2,5-dimethyl-3-(6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepin-3-yl)-1H-pyrrol-1-yl]benzoate
Homo sapiens
pH and temperature not specified in the publication
0.000383
N,N-diethyl-1-(3-methylphenyl)-1H-benzimidazole-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.001358
N-butyl-1-(3-methylphenyl)-1H-benzimidazole-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.000961
N-cyclopentyl-1-(3-methylphenyl)-1H-benzimidazole-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.000027
[1-(2-methoxyphenyl)-1H-benzimidazol-5-yl](piperidin-1-yl)methanone
Homo sapiens
pH and temperature not specified in the publication
0.000012
[1-(3-chlorophenyl)-1H-benzimidazol-5-yl](piperidin-1-yl)methanone
Homo sapiens
pH and temperature not specified in the publication
0.000019
[1-(3-methoxyphenyl)-1H-benzimidazol-5-yl](piperidin-1-yl)methanone
Homo sapiens
pH and temperature not specified in the publication
0.000022
[1-(3-methylphenyl)-1H-benzimidazol-5-yl](3-methylpiperidin-1-yl)methanone
Homo sapiens
pH and temperature not specified in the publication
0.000429
[1-(3-methylphenyl)-1H-benzimidazol-5-yl](3-phenylpiperidin-1-yl)methanone
Homo sapiens
pH and temperature not specified in the publication
0.00271
[1-(3-methylphenyl)-1H-benzimidazol-5-yl](4-methylpiperazin-1-yl)methanone
Homo sapiens
pH and temperature not specified in the publication
0.00304
[1-(3-methylphenyl)-1H-benzimidazol-5-yl](morpholin-4-yl)methanone
Homo sapiens
pH and temperature not specified in the publication
0.000019 - 0.000056
[1-(3-methylphenyl)-1H-benzimidazol-5-yl](piperidin-1-yl)methanone
0.000383
[1-(3-methylphenyl)-1H-benzimidazol-5-yl](pyrrolidin-1-yl)methanone
Homo sapiens
pH and temperature not specified in the publication
0.000048
[1-(3-methylphenyl)-1H-benzimidazol-5-yl][3-(propan-2-yl)piperidin-1-yl]methanone
Homo sapiens
pH and temperature not specified in the publication
0.000068
[1-(3-methylphenyl)-1H-benzimidazol-5-yl][3-(trifluoromethyl)piperidin-1-yl]methanone
Homo sapiens
pH and temperature not specified in the publication
0.001524
[1-(3-methylphenyl)-1H-benzimidazol-5-yl][4-(trifluoromethyl)piperidin-1-yl]methanone
Homo sapiens
pH and temperature not specified in the publication
0.000171
[1-(3-tert-butylphenyl)-1H-benzimidazol-5-yl](piperidin-1-yl)methanone
Homo sapiens
pH and temperature not specified in the publication
0.00022
[1-(4-chlorophenyl)-1H-benzimidazol-5-yl](piperidin-1-yl)methanone
Homo sapiens
pH and temperature not specified in the publication
0.00019
[1-(4-methoxyphenyl)-1H-benzimidazol-5-yl](piperidin-1-yl)methanone
Homo sapiens
pH and temperature not specified in the publication
0.00019
[1-(4-methylphenyl)-1H-benzimidazol-5-yl](piperidin-1-yl)methanone
Homo sapiens
pH and temperature not specified in the publication
0.000054
[1-(4-tert-butylphenyl)-1H-benzimidazol-5-yl](piperidin-1-yl)methanone
Homo sapiens
pH and temperature not specified in the publication
0.01
[4-(4-methoxyphenyl)piperazin-1-yl](4-[(phenylsulfanyl)methyl]phenyl)methanone
Homo sapiens
-
value above, pH 8, 25°C
0.000019
[1-(3-methylphenyl)-1H-benzimidazol-5-yl](piperidin-1-yl)methanone
Homo sapiens
pH and temperature not specified in the publication
0.000056
[1-(3-methylphenyl)-1H-benzimidazol-5-yl](piperidin-1-yl)methanone
Homo sapiens
-
pH 8, 25°C
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.